Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2019 | Apr. 30, 2019 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | DCPH | |
Entity Registrant Name | DECIPHERA PHARMACEUTICALS, INC. | |
Entity Central Index Key | 0001654151 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Accelerated Filer | |
Smaller Reporting Company | true | |
Emerging Growth Company | true | |
Entity Ex Transition Period | true | |
Entity Common Stock, Shares Outstanding | 38,189,052 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash and cash equivalents | $ 82,228 | $ 293,764 |
Marketable securities | 180,114 | 0 |
Prepaid expenses and other current assets | 4,103 | 7,273 |
Total current assets | 266,445 | 301,037 |
Long-term investment-restricted | 1,069 | 1,069 |
Property and equipment, net | 1,504 | 13,453 |
Operating lease, right-of-use assets | 670 | |
Total assets | 269,688 | 315,559 |
Current liabilities: | ||
Accounts payable | 10,937 | 8,308 |
Accrued expenses and other current liabilities | 16,333 | 13,709 |
Operating lease liabilities | 434 | 539 |
Notes payable to related party | 187 | 187 |
Total current liabilities | 27,891 | 22,743 |
Notes payable to related party, net of current portion | 1,076 | 1,107 |
Operating lease liabilities, net of current portion | 244 | 11,347 |
Other long-term liabilities | 481 | 381 |
Total liabilities | 29,692 | 35,578 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity: | ||
Preferred stock value | ||
Common stock value | 382 | 377 |
Additional paid-in capital | 582,700 | 575,327 |
Accumulated other comprehensive income | 21 | |
Accumulated deficit | (343,107) | (295,723) |
Total stockholders' equity | 239,996 | 279,981 |
Total liabilities and stockholders' equity | $ 269,688 | $ 315,559 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2019 | Dec. 31, 2018 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 125,000,000 | 125,000,000 |
Common stock, shares issued | 38,189,052 | 37,676,760 |
Common stock, shares outstanding | 38,189,052 | 37,676,760 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Income Statement [Abstract] | ||
Revenue | $ 0 | $ 0 |
Operating expenses: | ||
Research and development | 35,789 | 16,925 |
General and administrative | 13,236 | 5,026 |
Total operating expenses | 49,025 | 21,951 |
Loss from operations | (49,025) | (21,951) |
Other income (expense): | ||
Interest expense | (13) | (22) |
Interest and other income, net | 1,654 | 543 |
Total other income (expense), net | 1,641 | 521 |
Net loss | $ (47,384) | $ (21,430) |
Net loss per share-basic and diluted | $ (1.25) | $ (0.66) |
Weighted average common shares outstanding-basic and diluted | 38,057,018 | 32,594,074 |
Comprehensive loss: | ||
Net loss | $ (47,384) | $ (21,430) |
Other comprehensive income: | ||
Unrealized gains on marketable securities | 21 | |
Total other comprehensive income | 21 | |
Total comprehensive loss | $ (47,363) | $ (21,430) |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders Equity - USD ($) $ in Thousands | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Other Comprehensive Income [Member] | Accumulated Deficit [Member] |
Beginning balance at Dec. 31, 2017 | $ 183,973 | $ 326 | $ 379,516 | $ (195,869) | |
Beginning balance, shares at Dec. 31, 2017 | 32,591,686 | ||||
Issuance of common stock upon exercise of stock options | 10 | 10 | |||
Issuance of common stock upon exercise of stock options, Shares | 2,442 | ||||
Stock-based compensation expense | 2,037 | 2,037 | |||
Net loss | (21,430) | (21,430) | |||
Ending balance at Mar. 31, 2018 | 164,590 | $ 326 | 381,563 | (217,299) | |
Ending balance, shares at Mar. 31, 2018 | 32,594,128 | ||||
Beginning balance at Dec. 31, 2017 | 183,973 | $ 326 | 379,516 | (195,869) | |
Beginning balance, shares at Dec. 31, 2017 | 32,591,686 | ||||
Net loss | 99,900 | ||||
Ending balance at Dec. 31, 2018 | 279,981 | $ 377 | 575,327 | (295,723) | |
Ending balance, shares at Dec. 31, 2018 | 37,676,760 | ||||
Issuance of common stock upon exercise of stock options | 1,149 | $ 5 | 1,144 | ||
Issuance of common stock upon exercise of stock options, Shares | 512,292 | ||||
Stock-based compensation expense | 6,229 | 6,229 | |||
Unrealized gains on marketable securities | 21 | $ 21 | |||
Net loss | (47,384) | (47,384) | |||
Ending balance at Mar. 31, 2019 | $ 239,996 | $ 382 | $ 582,700 | $ 21 | $ (343,107) |
Ending balance, shares at Mar. 31, 2019 | 38,189,052 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Cash flows from operating activities: | ||
Net loss | $ (47,384) | $ (21,430) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock-based compensation expense | 6,229 | 2,037 |
Depreciation and amortization expense | 104 | 56 |
Net accretion of discounts on marketable securities | (486) | |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other current assets | 3,170 | 187 |
Operating lease, right-of-use assets | 143 | |
Accounts payable | 2,629 | 1,142 |
Accrued expenses and other current liabilities | 2,637 | 1,319 |
Operating lease liabilities | (148) | |
Other long-term liabilities | 100 | (5) |
Net cash used in operating activities | (33,006) | (16,694) |
Cash flows from investing activities: | ||
Purchases of marketable securities | (179,607) | |
Purchases of property and equipment | (41) | (151) |
Net cash used in investing activities | (179,648) | (151) |
Cash flows from financing activities: | ||
Repayment of notes payable to related party | (31) | (46) |
Proceeds from exercise of stock options | 1,149 | 10 |
Net cash provided by (used in) financing activities | 1,118 | (36) |
Net decrease in cash and cash equivalents | (211,536) | (16,881) |
Cash and cash equivalents at beginning of period | 293,764 | 196,754 |
Cash and cash equivalents at end of period | 82,228 | 179,873 |
Cash paid for interest | $ 13 | 22 |
Purchases of property and equipment included in accounts payable and accrued expenses | $ 97 |
Nature of the Business and Basi
Nature of the Business and Basis of Presentation | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Nature of the Business and Basis of Presentation | 1. Nature of the Business and Basis of Presentation Deciphera Pharmaceuticals, Inc. (the “Company”) is a clinical-stage biopharmaceutical company developing new drugs to improve the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of many cancer therapies. The Company’s targeted, small molecule drug candidates, designed using its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases, an important family of enzymes, that, when mutated or over expressed, are known to be directly involved in the growth and spread of many cancers. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Drug candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. On October 2, 2017, immediately prior to the completion of its initial public offering (“IPO”), the Company engaged in a series of transactions whereby Deciphera Pharmaceuticals, LLC became a wholly owned subsidiary of Deciphera Pharmaceuticals, Inc., a Delaware corporation. As part of the transactions, shareholders of Deciphera Pharmaceuticals, LLC exchanged their shares of Deciphera Pharmaceuticals, LLC for shares of Deciphera Pharmaceuticals, Inc. on a one-for-5.65 In October 2017, Deciphera Pharmaceuticals, Inc., completed the IPO, pursuant to which it issued and sold 8,166,496 shares of common stock at the IPO price of $17.00 per share, resulting in net proceeds of $124.6 million after deducting underwriting discounts and commissions and other offering expenses. Upon the closing of the IPO, the Company’s outstanding convertible preferred shares automatically converted into shares of common stock. In June 2018, the Company issued and sold 4,945,000 shares of its common stock in a follow-on The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has incurred recurring losses including net losses of $47.4 million and $99.9 million for the three months ended March 31, 2019 and the year ended December 31, 2018, respectively. As of March 31, 2019, the Company had an accumulated deficit of $343.1 million. The Company expects to continue to generate operating losses in the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12 months from the issuance date of these consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to fund its operations. The Company expects its expenses to increase substantially in connection with ongoing activities, particularly as the Company advances its preclinical activities and clinical trials for its drug candidates in development and engages in efforts to support commercialization should ripretinib receive regulatory approval. Accordingly, the Company will need to obtain substantial additional funding in connection with continuing operations. If the Company is unable to raise capital when needed, or on attractive terms, it could be forced to delay, reduce or eliminate its research or drug development programs or any future commercialization efforts. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. These consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. Unaudited Interim Financial Information The consolidated balance sheet at December 31, 2018 was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The accompanying unaudited consolidated financial statements as of March 31, 2019 and for the three months ended March 31, 2019 and 2018 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The Company believes, however, that the disclosures are adequate to make the information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K Fair Value Measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The Company’s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The fair value of the Company’s outstanding notes payable to a related party (see Note 5) as of each of March 31, 2019 and December 31, 2018 approximated $1.1 million. The fair value of the outstanding debt was estimated using a discounted cash flow analysis based on current market interest rates for debt issuances with similar remaining years to maturity, adjusted for credit risk, which represents a Level 3 measurement. Leases The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its operating right-of-use In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease non-lease non-lease right-of-use Comprehensive Loss Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with shareholders. For the three months ended March 31, 2019, the Company’s other comprehensive loss consisted of unrealized gains (losses) on marketable securities. For the three months ended March 31, 2018, there was no difference between net loss and comprehensive loss. Net Loss per Share Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share is computed by dividing the diluted net income (loss) by the weighted average number of common shares, including potential dilutive common shares assuming the dilutive effect as determined using the treasury stock method. For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss for each of the three months ended March 31, 2019 and 2018. The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact: As of March 31, 2019 2018 Options to purchase common stock 6,713,029 5,374,080 Unvested restricted common stock units 77,000 — 6,790,029 5,374,080 Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases 2016-02”). 2016-02 right-of-use 2016-02 2018-11, Leases catch-up The Company elected the “package of practical expedients”, which permits the Company not to reassess under the new standards for prior conclusions about lease identification, lease classification and initial direct costs. The Company did not apply the hindsight practical expedient when determining the lease term for existing leases and assessing impairment of expired or existing leases. The Company did not apply the recognition requirements to short-term leases and recognizes those lease payments in the consolidated statements of operations and comprehensive loss on a straight-line basis over the lease term. The Company elected the practical expedient to not separate lease and non-lease In connection with the adoption, the Company recognized right-of-use In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718) – Improvements to Nonemployee Share-Based Payment Accounting 2018-07”). non-employees ASU 2018-07 |
Marketable Securities and Fair
Marketable Securities and Fair Value Measurements | 3 Months Ended |
Mar. 31, 2019 | |
Investments, All Other Investments [Abstract] | |
Marketable Securities and Fair Value Measurements | 3. Marketable Securities and Fair Value Measurements As of March 31, 2019, marketable securities by security type consisted of (in thousands): Amortized Gross Gross Estimated Commercial paper (due within one year) $ 99,108 $ 6 $ (23 ) $ 99,091 U.S. Government securities (due within one year) 42,616 28 — 42,644 Certificates of deposit (due within one year) 38,369 10 — 38,379 Total $ 180,093 $ 44 $ (23 ) $ 180,114 The Company had no marketable securities as of December 31, 2018. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): Fair Value Measurements at March 31, 2019 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ — $ 5,403 $ — $ 5,403 Commercial paper — 49,219 — 49,219 Certificates of deposit — 19,002 — 19,002 Marketable securities: Commercial paper — 99,091 — 99,091 U.S. Government securities — 42,644 — 42,644 Certificates of deposit — 38,379 — 38,379 Total $ — $ 253,738 $ — $ 253,738 Fair Value Measurements at December 31, 2018 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ — $ 267,145 $ — $ 267,145 Total $ — $ 267,145 $ — $ 267,145 The table above as of March 31, 2019 and December 31, 2018 excludes a certificate of deposit in the amount of $1.1 million that the Company held to secure a letter of credit associated with a lease (see Note 7). During the three months ended March 31, 2019 and 2018, there were no transfers between Level 1, Level 2 and Level 3. |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 3 Months Ended |
Mar. 31, 2019 | |
Payables and Accruals [Abstract] | |
Accrued Expenses and Other Current Liabilities | 4. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): March 31, 2019 December 31, 2018 Accrued external research and development expenses $ 11,653 $ 8,761 Accrued payroll and related expenses 3,030 4,139 Accrued professional fees 1,468 747 Accrued other 182 62 $ 16,333 $ 13,709 |
Notes Payable to Related Party
Notes Payable to Related Party | 3 Months Ended |
Mar. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Notes Payable to Related Party | 5. Notes Payable to Related Party Notes payable to related party as of March 31, 2019 and December 31, 2018 consisted of outstanding borrowings under a loan agreement and a security agreement (together, the “CRL Construction Loan”) with Clinical Reference Laboratory, Inc. (“CRL”), a related party (see Note 9), as follows (in thousands): March 31, 2019 December 31, 2018 Notes payable to related party $ 1,263 $ 1,294 Less: Current portion (187 ) (187 ) Notes payable to related party, net of current portion $ 1,076 $ 1,107 Total interest expense was less than $0.1 million for each of the three months ended March 31, 2019 and 2018. |
Stock-Based Awards
Stock-Based Awards | 3 Months Ended |
Mar. 31, 2019 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Stock-Based Awards | 6. Stock-Based Awards The Company grants stock-based awards under its 2017 Stock Option and Incentive Plan (the “2017 Plan”) and is authorized to issue common stock under its 2017 Employee Stock Purchase Plan (“ESPP”). The Company also has outstanding stock options under its 2015 Equity Incentive Plan but is no longer granting awards under this plan. As of March 31, 2019, 2,116,883 shares of common stock were available for issuance under the 2017 Plan. As of March 31, 2019, 1,009,433 shares of common stock were available for issuance to participating employees under the ESPP. Stock-based compensation expense was classified in the statements of operations and comprehensive loss as follows (in thousands): Three Months Ended March 31, 2019 2018 Research and development expenses $ 1,692 $ 962 General and administrative expenses 4,537 1,075 $ 6,229 $ 2,037 As of March 31, 2019, total unrecognized compensation cost related to the unvested share-based awards was $46.8 million, which is expected to be recognized over a weighted average of 2.9 years. During the three months ended March 31, 2019, the Company recorded $2.4 million of stock-based compensation expense related to the modification of stock options pursuant to the transition agreement with its former President and Chief Executive Officer. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 7. Commitments and Contingencies Leases The Company has a three-year sublease agreement for office space in Waltham, Massachusetts that began in September 2016 and expires in September 2019. The Company has two five-year lease agreements for office and laboratory space in Lawrence, Kansas that began on January 1, 2016 and expire on December 31, 2020. The Company has two leases for additional office space in Lawrence, Kansas, that expire in December 2020. The lease agreements contain options to extend the lease terms however these extensions were not included in the right-of-use In addition, in August 2018, the Company entered into a nine-month sublease for additional office space in Waltham, Massachusetts that expires in May 2019. The expense related to this sublease is included in short-term lease costs for the three months ended March 31, 2019. The Company’s leases require the Company to pay for certain operating expenses based on actual costs incurred and therefore as the amounts are variable in nature are expensed in the period incurred and included in variable lease costs for the three months ended March 31, 2019. Payment escalations specified in the lease are recognized on a straight-line basis over the lease terms. The components of lease expense were as follows (in thousands): Three Months Ended Operating lease cost $ 155 Short-term lease cost 94 Variable lease cost 92 $ 341 Other information Cash paid for amounts included in the measurement of operating lease liabilities $ 160 Operating lease liabilities arising from obtaining new right-of-use $ — Weighted-average remaining lease term—operating leases (in years) 1.51 Weighted-average discount rate—operating leases 5.91 % Future annual minimum lease payments under operating leases as of March 31, 2019 were as follows (in thousands): Remainder of 2019 (nine months) $ 378 2020 333 Total future minimum lease payments 711 Less: imputed interest (33 ) Total operating lease liabilities $ 678 Included in the consolidated balance sheet: Current operating lease liabilities $ 434 Operating lease liabilities, net of current portion 244 Total operating lease liabilities $ 678 As previously disclosed in the Company’s 2018 Annual Report on Form 10-K ASC 840, Leases, Year Ending December 31, 2019 $ 726 2020 333 $ 1,059 In May 2018, the Company entered into a lease for office space in Waltham, Massachusetts, which is expected to commence in 2019. The initial term of the lease expires in November 2029, unless terminated earlier in accordance with the terms of the lease. The Company is entitled to two five-year options to extend. The initial annual base rent is approximately $2.0 million and will increase annually for a total of $22.4 million over the lease term. The Company is obligated to pay its portion of real estate taxes and costs related to the premises, including costs of operations, maintenance, repair, replacement and management of the new leased premises. The Company is required to maintain a cash balance of $1.1 million to secure a letter of credit associated with the lease. This amount was classified as long-term investment—restricted in the consolidated balance sheet as of March 31, 2019. Prior to the adoption of ASC 2016-02, construction-in-progress build-to-suit 2016-02, build-to right-of-use 2016-02. As previously disclosed in the Company’s 2018 Annual Report on Form 10-K ASC 840, Leases, Year Ending December 31, 2019 $ 170 2020 2,043 2021 2,088 2022 2,132 2023 2,177 Thereafter 13,783 $ 22,393 KBA Grants Prior to 2014, the Company received funding from two research and development grants from the Kansas Bioscience Authority, or KBA, totaling $2.0 million and no further amounts will be received under these grants. Pursuant to Kansas law, the Company may be required to repay some or all of the financial assistance received from the KBA, subject to the discretion of the KBA, if the Company relocates the operations in which the KBA invested outside of the State of Kansas, if the Company initiates procedures to dissolve and wind up or cease operations within ten years after receiving such financial assistance, or upon certain significant changes to ownership of the Company. The Company will only account for the repayment of the grants if it becomes probable that the Company will be required to repay any funds previously received. Legal Proceedings The Company is not currently a party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as they are incurred. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of March 31, 2019 or December 31, 2018. |
401(k) Savings Plan
401(k) Savings Plan | 3 Months Ended |
Mar. 31, 2019 | |
Retirement Benefits [Abstract] | |
401(k) Savings Plan | 8. 401(k) Savings Plan Effective January 1, 2018, the Company adopted the Deciphera Pharmaceuticals 401(k) Plan (the “401(k) Plan”), a defined contribution plan under Section 401(k) of the Internal Revenue Code, whereby the Company provides matching contributions of 100% of each employee’s contribution up to a maximum matching contribution of 3% of the employee’s eligible compensation and at a rate of 50% of each employee’s contribution in excess of 3% up to a maximum of 5% of the employee’s eligible compensation. Total employer matching contributions related to the 401(k) Plan were $0.3 million and $0.2 million, for the three months ended March 31, 2019 and 2018, respectively. |
Related Parties
Related Parties | 3 Months Ended |
Mar. 31, 2019 | |
Related Party Transactions [Abstract] | |
Related Parties | 9. Related Parties Clinical Reference Laboratory, Inc. One of the members of the Company’s board of directors is the Chief Executive Officer of CRL. CRL is the owner of approximately 31% of Brightstar, a holder of more than 5% of the Company’s common stock. The Company is a party to a loan agreement and a security agreement, each dated as of June 11, 2010, with CRL. The Company borrowed an aggregate of $2.8 million under the loan agreement to finance improvements to the Company’s biology and chemistry laboratories in Lawrence, Kansas. In December 2016, the loan was assigned to CHC, Inc., a related party, which owns 100% of CRL. Borrowings under the loan bear interest at a fixed rate equal to 6.0% per annum and the Company is required to make monthly payments of principal and interest, based on a 15-year The Company is party to a master services agreement, effective as of May 20, 2013, with CRL under which the Company purchased and expects to continue to purchase laboratory services. Under the agreement, the Company has agreed to use CRL on an exclusive basis for certain laboratory testing needs. For each of the three months ended March 31, 2019 and 2018, the Company recorded $0.2 million of research and development expense incurred under this agreement, of which $0.2 million and less than $0.1 million, respectively, was paid to CRL during those same periods. As of March 31, 2019 and December 31, 2018, total amounts owed to CRL for laboratory services were $0.1 million and $0.2 million, respectively, which amounts were included in accounts payable and accrued expenses. The Company is not committed to purchase any minimum amounts under the agreement. |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2019 | |
Subsequent Events [Abstract] | |
Subsequent Events | 10. Subsequent Events On April 29, 2019, the Company amended its lease for office space in Waltham, Massachusetts to add an additional 38,003 square feet of space for a total of 82,346 square feet of space. The lease term for the additional space is expected to commence on January 1, 2020 and expire on November 30, 2029. The Company is entitled to two five-year options to extend. The initial annual base rent for the additional space is approximately $1.9 million and will increase annually for a total of $18.2 million over the lease term. The Company will be required pay its share of operating expenses, taxes and other expenses related to the additional leased premises. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. |
Unaudited Interim Financial Information | Unaudited Interim Financial Information The consolidated balance sheet at December 31, 2018 was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The accompanying unaudited consolidated financial statements as of March 31, 2019 and for the three months ended March 31, 2019 and 2018 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The Company believes, however, that the disclosures are adequate to make the information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K |
Fair Value Measurements | Fair Value Measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The Company’s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The fair value of the Company’s outstanding notes payable to a related party (see Note 5) as of each of March 31, 2019 and December 31, 2018 approximated $1.1 million. The fair value of the outstanding debt was estimated using a discounted cash flow analysis based on current market interest rates for debt issuances with similar remaining years to maturity, adjusted for credit risk, which represents a Level 3 measurement. |
Leases | Leases The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its operating right-of-use In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease non-lease non-lease right-of-use |
Comprehensive Loss | Comprehensive Loss Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with shareholders. For the three months ended March 31, 2019, the Company’s other comprehensive loss consisted of unrealized gains (losses) on marketable securities. For the three months ended March 31, 2018, there was no difference between net loss and comprehensive loss. |
Net Loss per Share | Net Loss per Share Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share is computed by dividing the diluted net income (loss) by the weighted average number of common shares, including potential dilutive common shares assuming the dilutive effect as determined using the treasury stock method. For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss for each of the three months ended March 31, 2019 and 2018. The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact: As of March 31, 2019 2018 Options to purchase common stock 6,713,029 5,374,080 Unvested restricted common stock units 77,000 — 6,790,029 5,374,080 |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases 2016-02”). 2016-02 right-of-use 2016-02 2018-11, Leases catch-up The Company elected the “package of practical expedients”, which permits the Company not to reassess under the new standards for prior conclusions about lease identification, lease classification and initial direct costs. The Company did not apply the hindsight practical expedient when determining the lease term for existing leases and assessing impairment of expired or existing leases. The Company did not apply the recognition requirements to short-term leases and recognizes those lease payments in the consolidated statements of operations and comprehensive loss on a straight-line basis over the lease term. The Company elected the practical expedient to not separate lease and non-lease In connection with the adoption, the Company recognized right-of-use In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718) – Improvements to Nonemployee Share-Based Payment Accounting 2018-07”). non-employees ASU 2018-07 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Summary of Potential Dilutive Securities | The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact: As of March 31, 2019 2018 Options to purchase common stock 6,713,029 5,374,080 Unvested restricted common stock units 77,000 — 6,790,029 5,374,080 |
Marketable Securities and Fai_2
Marketable Securities and Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Investments, All Other Investments [Abstract] | |
Schedule of Marketable Securities | As of March 31, 2019, marketable securities by security type consisted of (in thousands): Amortized Gross Gross Estimated Commercial paper (due within one year) $ 99,108 $ 6 $ (23 ) $ 99,091 U.S. Government securities (due within one year) 42,616 28 — 42,644 Certificates of deposit (due within one year) 38,369 10 — 38,379 Total $ 180,093 $ 44 $ (23 ) $ 180,114 |
Schedule of Financial Assets Measured at Fair Value on a Recurring Basis | The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): Fair Value Measurements at March 31, 2019 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ — $ 5,403 $ — $ 5,403 Commercial paper — 49,219 — 49,219 Certificates of deposit — 19,002 — 19,002 Marketable securities: Commercial paper — 99,091 — 99,091 U.S. Government securities — 42,644 — 42,644 Certificates of deposit — 38,379 — 38,379 Total $ — $ 253,738 $ — $ 253,738 Fair Value Measurements at December 31, 2018 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ — $ 267,145 $ — $ 267,145 Total $ — $ 267,145 $ — $ 267,145 |
Accrued Expenses and Other Cu_2
Accrued Expenses and Other Current Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses and Other Current Liabilities | Accrued expenses and other current liabilities consisted of the following (in thousands): March 31, 2019 December 31, 2018 Accrued external research and development expenses $ 11,653 $ 8,761 Accrued payroll and related expenses 3,030 4,139 Accrued professional fees 1,468 747 Accrued other 182 62 $ 16,333 $ 13,709 |
Notes Payable to Related Party
Notes Payable to Related Party (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of Notes Payable to Related Party | Notes payable to related party as of March 31, 2019 and December 31, 2018 consisted of outstanding borrowings under a loan agreement and a security agreement (together, the “CRL Construction Loan”) with Clinical Reference Laboratory, Inc. (“CRL”), a related party (see Note 9), as follows (in thousands): March 31, 2019 December 31, 2018 Notes payable to related party $ 1,263 $ 1,294 Less: Current portion (187 ) (187 ) Notes payable to related party, net of current portion $ 1,076 $ 1,107 |
Stock-Based Awards (Tables)
Stock-Based Awards (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Classification of Stock-Based Compensation Expense | Stock-based compensation expense was classified in the statements of operations and comprehensive loss as follows (in thousands): Three Months Ended March 31, 2019 2018 Research and development expenses $ 1,692 $ 962 General and administrative expenses 4,537 1,075 $ 6,229 $ 2,037 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Components of Lease Expense | The components of lease expense were as follows (in thousands): Three Months Ended Operating lease cost $ 155 Short-term lease cost 94 Variable lease cost 92 $ 341 Other information Cash paid for amounts included in the measurement of operating lease liabilities $ 160 Operating lease liabilities arising from obtaining new right-of-use $ — Weighted-average remaining lease term—operating leases (in years) 1.51 Weighted-average discount rate—operating leases 5.91 % |
Summary of Future Minimum Lease Payments under Operating Leases | Future annual minimum lease payments under operating leases as of March 31, 2019 were as follows (in thousands): Remainder of 2019 (nine months) $ 378 2020 333 Total future minimum lease payments 711 Less: imputed interest (33 ) Total operating lease liabilities $ 678 Included in the consolidated balance sheet: Current operating lease liabilities $ 434 Operating lease liabilities, net of current portion 244 Total operating lease liabilities $ 678 |
Accounting Standards Update 2016-02 [Member] | |
Summary of Future Minimum Lease Payments under Operating Leases | As previously disclosed in the Company’s 2018 Annual Report on Form 10-K ASC 840, Leases, Year Ending December 31, 2019 $ 726 2020 333 $ 1,059 |
Summary of Future Minimum Lease Payments | As previously disclosed in the Company’s 2018 Annual Report on Form 10-K ASC 840, Leases, Year Ending December 31, 2019 $ 170 2020 2,043 2021 2,088 2022 2,132 2023 2,177 Thereafter 13,783 $ 22,393 |
Nature of the Business and Ba_2
Nature of the Business and Basis of Presentation - Additional Information (Detail) $ / shares in Units, $ in Thousands | Oct. 02, 2017 | Jun. 30, 2018USD ($)$ / sharesshares | Oct. 31, 2017USD ($)$ / sharesshares | Mar. 31, 2019USD ($) | Mar. 31, 2018USD ($) | Dec. 31, 2018USD ($) |
Nature Of Business And Basis Of Presentation [Line Items] | ||||||
Share conversion ratio | 5.65 | |||||
Accumulated deficit | $ (343,107) | $ (295,723) | ||||
Net loss | $ (47,384) | $ (21,430) | $ 99,900 | |||
Common Stock [Member] | ||||||
Nature Of Business And Basis Of Presentation [Line Items] | ||||||
Net proceeds from initial public offering | $ 185,300 | |||||
IPO [Member] | ||||||
Nature Of Business And Basis Of Presentation [Line Items] | ||||||
Number of shares issued and sold | shares | 8,166,496 | |||||
Additional offering price of common stock | $ / shares | $ 17 | |||||
Net proceeds from initial public offering | $ 124,600 | |||||
IPO [Member] | Common Stock [Member] | ||||||
Nature Of Business And Basis Of Presentation [Line Items] | ||||||
Number of shares issued and sold | shares | 4,945,000 | |||||
Additional offering price of common stock | $ / shares | $ 40 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Significant Accounting Policies [Line Items] | ||
Right of use assets | $ 670 | |
Lease liabilities | 678 | $ 11,900 |
Construction in Progress [Member] | ||
Significant Accounting Policies [Line Items] | ||
Company capitalized construction-in-progress lease financing obligation | 11,900 | |
Accounting Standards Update 2016-02 [Member] | ||
Significant Accounting Policies [Line Items] | ||
Right of use assets | 800 | |
Lease liabilities | 800 | |
CRL Construction Loan [Member] | ||
Significant Accounting Policies [Line Items] | ||
Fair value of outstanding notes payable to related party | $ 1,100 | $ 1,100 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Summary of Potential Dilutive Securities (Detail) - shares | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potential dilutive securities excluded from computation of diluted net loss per common share | 6,790,029 | 5,374,080 |
Unvested Restricted Common Stock Units [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potential dilutive securities excluded from computation of diluted net loss per common share | 77,000 | |
Options to Purchase Common Shares [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potential dilutive securities excluded from computation of diluted net loss per common share | 6,713,029 | 5,374,080 |
Marketable Securities and Fai_3
Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Detail) $ in Thousands | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Fair Value Measurements Of Financial Instruments [Line Items] | |
Debt Securities, Available-for-sale, Amortized Cost | $ 180,093 |
Debt Securities, Available-for-sale, Gross Unrealized Gains | 44 |
Debt Securities, Available-for-sale, Gross Unrealized Losses | (23) |
Debt Securities, Available-for-sale, Estimated Fair Value | 180,114 |
Commercial Paper [Member] | |
Fair Value Measurements Of Financial Instruments [Line Items] | |
Debt Securities, Available-for-sale, Amortized Cost | 99,108 |
Debt Securities, Available-for-sale, Gross Unrealized Gains | 6 |
Debt Securities, Available-for-sale, Gross Unrealized Losses | (23) |
Debt Securities, Available-for-sale, Estimated Fair Value | 99,091 |
US Government Debt Securities [Member] | |
Fair Value Measurements Of Financial Instruments [Line Items] | |
Debt Securities, Available-for-sale, Amortized Cost | 42,616 |
Debt Securities, Available-for-sale, Gross Unrealized Gains | 28 |
Debt Securities, Available-for-sale, Estimated Fair Value | 42,644 |
Certificates of Deposit [Member] | |
Fair Value Measurements Of Financial Instruments [Line Items] | |
Debt Securities, Available-for-sale, Amortized Cost | 38,369 |
Debt Securities, Available-for-sale, Gross Unrealized Gains | 10 |
Debt Securities, Available-for-sale, Estimated Fair Value | $ 38,379 |
Marketable Securities and Fai_4
Marketable Securities and Fair Value Measurements - Additional Information (Detail) - USD ($) | 3 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Fair Value of Assets and Liabilities Measured on Non Recurring Basis [Line Items] | |||
Marketable securities | $ 180,114,000 | $ 0 | |
Transfers between Level 1, Level 2 and Level 3 | 0 | $ 0 | |
Certificates of Deposit [Member] | Letter of Credit [Member] | |||
Fair Value of Assets and Liabilities Measured on Non Recurring Basis [Line Items] | |||
Cash balance held to secure letter of credit associated with lease | $ 1,100,000 | $ 1,100,000 |
Marketable Securities and Fai_5
Marketable Securities and Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Cash equivalents: | ||
Total Cash equivalents | $ 267,145 | |
Marketable securities: | ||
Total | $ 253,738 | |
Commercial Paper [Member] | ||
Marketable securities: | ||
Total Marketable securities | 99,091 | |
US Government Debt Securities [Member] | ||
Marketable securities: | ||
Total Marketable securities | 42,644 | |
Certificates of Deposit [Member] | ||
Marketable securities: | ||
Total Marketable securities | 38,379 | |
Money Market Funds [Member] | ||
Cash equivalents: | ||
Total Cash equivalents | 5,403 | 267,145 |
Commercial Paper [Member] | ||
Cash equivalents: | ||
Total Cash equivalents | 49,219 | |
Certificates of Deposit [Member] | ||
Cash equivalents: | ||
Total Cash equivalents | 19,002 | |
Level 2 [Member] | ||
Cash equivalents: | ||
Total Cash equivalents | 267,145 | |
Marketable securities: | ||
Total | 253,738 | |
Level 2 [Member] | Commercial Paper [Member] | ||
Marketable securities: | ||
Total Marketable securities | 99,091 | |
Level 2 [Member] | US Government Debt Securities [Member] | ||
Marketable securities: | ||
Total Marketable securities | 42,644 | |
Level 2 [Member] | Certificates of Deposit [Member] | ||
Marketable securities: | ||
Total Marketable securities | 38,379 | |
Level 2 [Member] | Money Market Funds [Member] | ||
Cash equivalents: | ||
Total Cash equivalents | 5,403 | $ 267,145 |
Level 2 [Member] | Commercial Paper [Member] | ||
Cash equivalents: | ||
Total Cash equivalents | 49,219 | |
Level 2 [Member] | Certificates of Deposit [Member] | ||
Cash equivalents: | ||
Total Cash equivalents | $ 19,002 |
Accrued Expenses and Other Cu_3
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Accounts Payable and Accrued Liabilities [Abstract] | ||
Accrued external research and development expenses | $ 11,653 | $ 8,761 |
Accrued payroll and related expenses | 3,030 | 4,139 |
Accrued professional fees | 1,468 | 747 |
Accrued other | 182 | 62 |
Accrued expenses and other current liabilities | $ 16,333 | $ 13,709 |
Notes Payable to Related Part_2
Notes Payable to Related Party - Schedule of Notes Payable to Related Party (Detail) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Related Party Transaction [Line Items] | ||
Less: Current portion | $ (187) | $ (187) |
Notes payable to related party, net of current portion | 1,076 | 1,107 |
CRL Construction Loan [Member] | Clinical Reference Laboratory, Inc. [Member] | ||
Related Party Transaction [Line Items] | ||
Notes payable to related party | 1,263 | 1,294 |
Less: Current portion | (187) | (187) |
Notes payable to related party, net of current portion | $ 1,076 | $ 1,107 |
Notes Payable to Related Part_3
Notes Payable to Related Party - Additional Information (Detail) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Maximum [Member] | Clinical Reference Laboratory, Inc. [Member] | CRL Construction Loan [Member] | ||
Related Party Transaction [Line Items] | ||
Total interest expense | $ 100,000 | $ 100,000 |
Stock-Based Awards - Additional
Stock-Based Awards - Additional Information (Detail) $ in Millions | 3 Months Ended |
Mar. 31, 2019USD ($)shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost related to unvested share-based awards | $ | $ 46.8 |
Unrecognized compensation cost related to unvested share-based awards, period for recognition | 2 years 10 months 24 days |
President And Chief Executive Officer [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Stock-based compensation expense related to modification | $ | $ 2.4 |
2017 Stock Option and Incentive Plan [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Common stock available for issuance | shares | 2,116,883 |
Employee Stock Purchase Plan (ESPP) [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Common stock available for issuance | shares | 1,009,433 |
Stock-Based Awards - Classifica
Stock-Based Awards - Classification of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | $ 6,229 | $ 2,037 |
Research and Development Expenses [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | 1,692 | 962 |
General and Administrative Expenses [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | $ 4,537 | $ 1,075 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) $ in Millions | Dec. 31, 2013USD ($)award | Aug. 30, 2018 | Dec. 31, 2015Lease | Mar. 31, 2019USD ($)Lease | Dec. 31, 2018USD ($) |
Other Commitments [Line Items] | |||||
Lease commencement period | 2019 | ||||
Lease expiration period | 2029-11 | ||||
Lessee, finance lease, existence of option to extend | true | ||||
Lessee, finance lease, existence of option to terminate | true | ||||
Options to extend terms of the lease | Two five-year | ||||
Initial annual base rent | $ 2 | ||||
Total operating lease rent expense | 22.4 | ||||
Company capitalized construction-in-progress lease financing obligation | $ 11.9 | ||||
Cash [Member] | Letter of Credit [Member] | |||||
Other Commitments [Line Items] | |||||
Cash balance to secure letter of credit associated with lease | $ 1.1 | ||||
KBA Grants [Member] | |||||
Other Commitments [Line Items] | |||||
Number of awards grants | award | 2 | ||||
Amount of grants awarded | $ 2 | ||||
Kansas(KS) [Member] | Lease Agreement for Office and Laboratory Space in Lawrence, Kansas [Member] | |||||
Other Commitments [Line Items] | |||||
Number of lease agreement | Lease | 2 | ||||
Operating lease expiry date | Dec. 31, 2020 | ||||
Lease term | 5 years | ||||
Kansas(KS) [Member] | Lease for Additional Office Space in Lawrence, Kansas [Member] | |||||
Other Commitments [Line Items] | |||||
Number of lease agreement | Lease | 2 | ||||
Operating lease expiry date | Dec. 31, 2020 | ||||
Massachusetts (MA) [Member] | Sublease Agreement for Office Space in Waltham, Massachusetts [Member] | |||||
Other Commitments [Line Items] | |||||
Sublease term | 3 years | ||||
Sublease expiration date | Sep. 30, 2019 | ||||
Massachusetts (MA) [Member] | Sublease for Additional Agreement for Office Space in Waltham, Massachusetts [Member] | |||||
Other Commitments [Line Items] | |||||
Sublease term | 9 months | ||||
Sublease expiration date | May 31, 2019 |
Commitments and Contingencies_2
Commitments and Contingencies - Components of Lease Expense (Detail) $ in Thousands | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Leases, Operating [Abstract] | |
Operating lease cost | $ 155 |
Short-term lease cost | 94 |
Variable lease cost | 92 |
Total lease cost | 341 |
Cash paid for amounts included in the measurement of operating lease liabilities | 160 |
Operating lease liabilities arising from obtaining new right-of-use assets | $ 0 |
Weighted-average remaining lease term-operating leases (in years) | 1 year 6 months 3 days |
Weighted-average discount rate-operating leases | 5.91% |
Commitments and Contingencies_3
Commitments and Contingencies - Summary of Future Minimum Lease Payments under Operating Leases (Detail) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] | ||
Remainder of 2019 (nine months) | $ 378 | |
2019 | $ 726 | |
2020 | 333 | 333 |
Future minimum lease payments due | 711 | 1,059 |
Less: imputed interest | (33) | |
Total operating lease liabilities | 678 | 11,900 |
Current operating lease liabilities | 434 | 539 |
Operating lease liabilities, net of current portion | 244 | 11,347 |
Total operating lease liabilities | $ 678 | $ 11,900 |
Commitments and Contingencies_4
Commitments and Contingencies - Future Minimum Lease Payments Commitments Lease (Detail) $ in Thousands | Dec. 31, 2018USD ($) |
Contractual Obligation, Fiscal Year Maturity Schedule [Abstract] | |
2019 | $ 170 |
2020 | 2,043 |
2021 | 2,088 |
2022 | 2,132 |
2023 | 2,177 |
Thereafter | 13,783 |
Total | $ 22,393 |
401(k) Savings Plan - Additiona
401(k) Savings Plan - Additional Information (Detail) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Defined Contribution Plan Disclosure [Line Items] | ||
Percentage of matching contribution to plan | 50.00% | |
Clinical Reference Laboratory, Inc. [Member] | ||
Defined Contribution Plan Disclosure [Line Items] | ||
Defined contribution plan description | Effective January 1, 2018, the Company adopted the Deciphera Pharmaceuticals 401(k) Plan (the "401(k) Plan"), a defined contribution plan under Section 401(k) of the Internal Revenue Code, whereby the Company provides matching contributions of 100% of each employee's contribution up to a maximum matching contribution of 3% of the employee's eligible compensation and at a rate of 50% of each employee's contribution in excess of 3% up to a maximum of 5% of the employee's eligible compensation. | |
Percentage of matching contribution to plan | 100.00% | |
Matching contributions to the plan by employer | $ 0.3 | $ 0.2 |
Maximum [Member] | ||
Defined Contribution Plan Disclosure [Line Items] | ||
Percentage of salary for matching contribution per employee on time-based vesting | 5.00% | |
Maximum [Member] | Clinical Reference Laboratory, Inc. [Member] | ||
Defined Contribution Plan Disclosure [Line Items] | ||
Employee earnings subject to employer match | 3.00% | |
Minimum [Member] | ||
Defined Contribution Plan Disclosure [Line Items] | ||
Percentage of salary for matching contribution per employee on time-based vesting | 3.00% |
Related Parties - Additional In
Related Parties - Additional Information (Detail) - USD ($) | 3 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Related Party Transaction [Line Items] | |||
Research and development expense | $ 35,789,000 | $ 16,925,000 | |
Clinical Reference Laboratory, Inc. [Member] | |||
Related Party Transaction [Line Items] | |||
Laboratory services | 100,000 | $ 200,000 | |
Clinical Reference Laboratory, Inc. [Member] | Loan and Security Agreement [Member] | |||
Related Party Transaction [Line Items] | |||
Aggregate borrowings | 2,800,000 | ||
Debt instrument principal and interest payment | 100,000 | 100,000 | |
Principal amount owed under loan agreement | 1,300,000 | 1,300,000 | |
Clinical Reference Laboratory, Inc. [Member] | Service Agreement [Member] | |||
Related Party Transaction [Line Items] | |||
Research and development expense | 200,000 | 200,000 | |
Payments for research and development expense | $ 200,000 | $ 100,000 | |
Clinical Reference Laboratory, Inc. [Member] | CHC, Inc. [Member] | Loan and Security Agreement [Member] | |||
Related Party Transaction [Line Items] | |||
Ownership percentage | 100.00% | ||
Fixed interest rate | 6.00% | ||
Debt instrument payment term | 15-year straight-line amortization schedule | ||
Debt instrument term | 15 years | ||
Clinical Reference Laboratory, Inc. [Member] | CRL Construction Loan [Member] | |||
Related Party Transaction [Line Items] | |||
Principal amount owed under loan agreement | $ 1,263,000 | $ 1,294,000 | |
Clinical Reference Laboratory, Inc. [Member] | Maximum [Member] | CRL Construction Loan [Member] | |||
Related Party Transaction [Line Items] | |||
Interest expense on borrowings | $ 100,000 | $ 100,000 | |
Clinical Reference Laboratory, Inc. [Member] | Brightstar [Member] | |||
Related Party Transaction [Line Items] | |||
Ownership percentage | 31.00% | ||
Clinical Reference Laboratory, Inc. [Member] | Brightstar [Member] | Minimum [Member] | |||
Related Party Transaction [Line Items] | |||
Percentage of common stock holding | 5.00% |
Subsequent Events - Additional
Subsequent Events - Additional Information (Detail) $ in Millions | Apr. 29, 2019USD ($)ft² | Mar. 31, 2019USD ($) |
Subsequent Event [Line Items] | ||
Total operating lease over the lease term | $ 2 | |
Subsequent Event [Member] | Office Space in Waltham [Member] | Massachusetts [Member] | ||
Subsequent Event [Line Items] | ||
Additional area of lease space | ft² | 38,003 | |
Total lease area | ft² | 82,346 | |
Lease commencement date | Jan. 1, 2020 | |
Lease expiation date | Nov. 30, 2029 | |
Lessee, operating lease, existence of option to extend | true | |
Options to extend terms of the lease | Two five-year | |
Options to extend terms of the lease | 5 years | |
Initial annual base rent for the additional space | $ 1.9 | |
Total operating lease over the lease term | $ 18.2 |